DXR - Daxor says Q2 sales of single-use diagnostic kits up nearly 50% Y/Y
- Daxor ( NASDAQ: DXR ) on Wednesday said Q2 sales of its single-use diagnostic kits by volume rose 49.4% Y/Y.
- The company attributed the increase to a combination of factors, including the purchase and leasing of capital equipment, reference lab use and the opening of 12 new commercial and academic accounts.
- The Q2 sales of single-use diagnostic kits rose 10.4% compared to Q1 2022.
- Daxor ( DXR ) makes the BVA-100 diagnostic, which provides measurement of blood volume status and composition.
- DXR also said an academic center in the Illinois Medical Center had recently placed an order for the company's BVA-100 tests.
- DXR stock was marginally higher in the first ten minutes of trading.
For further details see:
Daxor says Q2 sales of single-use diagnostic kits up nearly 50% Y/Y